Clinical Trials Directory

Trials / Completed

CompletedNCT01152996

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,075 (actual)
Sponsor
Takeda · Industry
Sex
All
Age
18 Years – 77 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.

Detailed description

Depression has been recognized as a chronic illness that imposes a significant burden on individuals, families and society. Major depressive disorder (MDD) is among the most important causes of disability worldwide, in both developing and developed countries. Major depressive disorder is reported to be the most common mood disorder, with a lifetime prevalence of about 15% and as high as 25% in women. Major depressive disorder is characterized by the presence of 1 or more major depressive episodes that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration. This is a multicenter extension study designed to allow eligible patients who have completed short-term efficacy and safety studies LuAA21004\_315 (NCT01153009), LuAA21004\_316 (NCT01163266) and LuAA21004\_317 (NCT01179516) to receive the 52-week treatment with vortioxetine in this open-label extension study. Participants are expected to return to the site for approximately 13 visits. A safety follow-up call will be made 4 weeks after completion of the 52-week treatment period.

Conditions

Interventions

TypeNameDescription
DRUGVortioxetineVortioxetine tablets

Timeline

Start date
2010-09-01
Primary completion
2013-05-01
Completion
2013-05-01
First posted
2010-06-29
Last updated
2014-05-28
Results posted
2014-05-28

Source: ClinicalTrials.gov record NCT01152996. Inclusion in this directory is not an endorsement.